Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Allo save search
10-Q: Quarterly report which provides a continuing view of a company's financial position
Published: 2023-05-03 (Crawled : 21:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -0.35%
H: 20.53%
C: 13.16%
report financial
10-Q: Quarterly report which provides a continuing view of a company's financial position
Published: 2022-11-02 (Crawled : 21:00) - allogene.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: -7.47%
H: 4.2%
C: 1.17%
report financial
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
ema als trials trial therapeutics phase 1 positive
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
Published: 2021-06-04 (Crawled : 13:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 1.09%
H: 0.56%
C: -2.15%
phase 1 positive phase 3
Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
Published: 2021-05-19 (Crawled : 21:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
|
| O: 11.52%
H: 0.06%
C: -15.43%
positive results phase 1 positive results phase 3
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
Published: 2020-12-05 (Crawled : 18:00) - globenewswire.com
ALLO | $3.455 -1.57% -1.59% 1.2M
|
Health Technology
| Email alert
Add to watchlist
therapy positive results phase 3 phase 1 phase 2 t-cell
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.